Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide
Authors
Keywords
-
Journal
Multiple Sclerosis Journal
Volume -, Issue -, Pages 135245851985572
Publisher
SAGE Publications
Online
2019-06-14
DOI
10.1177/1352458519855722
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PACTRIMS 2017
- (2018) Multiple Sclerosis Journal
- PACTRIMS 2017
- (2018) Multiple Sclerosis Journal
- Poster Session 2
- (2018) Multiple Sclerosis Journal
- Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
- (2016) Ludwig Kappos et al. Multiple Sclerosis Journal
- Long-term safety and efficacy of teriflunomide
- (2016) Paul O'Connor et al. NEUROLOGY
- Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
- (2016) Ludwig Kappos et al. Multiple Sclerosis Journal
- Optimizing treatment success in multiple sclerosis
- (2015) Tjalf Ziemssen et al. JOURNAL OF NEUROLOGY
- Fingolimod effect on brain volume loss independently contributes to its effect on disability
- (2015) MP Sormani et al. Multiple Sclerosis Journal
- Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
- (2015) D. H. Miller et al. NEUROLOGY
- Fingolimod effect on brain volume loss independently contributes to its effect on disability
- (2015) MP Sormani et al. Multiple Sclerosis Journal
- Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study
- (2014) Douglas L. Arnold et al. JOURNAL OF NEUROLOGY
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis
- (2013) Maria Pia Sormani et al. ANNALS OF NEUROLOGY
- Brain atrophy and lesion load predict long term disability in multiple sclerosis
- (2013) Veronica Popescu et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Magnetic resonance imaging outcomes from a phase III trial of teriflunomide
- (2013) Jerry S Wolinsky et al. Multiple Sclerosis Journal
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluating and reducing the impact of white matter lesions on brain volume measurements
- (2011) Marco Battaglini et al. HUMAN BRAIN MAPPING
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
- (2010) N. De Stefano et al. NEUROLOGY
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cortical Lesions and Atrophy Associated With Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis
- (2009) Massimiliano Calabrese et al. ARCHIVES OF NEUROLOGY
- Gray matter atrophy in multiple sclerosis: A longitudinal study
- (2008) Elizabeth Fisher et al. ANNALS OF NEUROLOGY
- Brain Atrophy Assessment in Multiple Sclerosis: Importance and Limitations
- (2008) Antonio Giorgio et al. NEUROIMAGING CLINICS OF NORTH AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More